Advertisement
CMOPF vs CSPCY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMOPF is a Hold and CSPCY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CMOPF’s FA Score shows that 1 FA rating(s) are green whileCSPCY’s FA Score has 2 green FA rating(s).
- CMOPF’s FA Score: 1 green, 4 red.
- CSPCY’s FA Score: 2 green, 3 red.
Price Growth
CMOPF (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while CSPCY (@Pharmaceuticals: Major) price change was +1.68% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +10.48%, and the average quarterly price growth was +8.86%.
Industries' Descriptions
@Pharmaceuticals: Major (+1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| CMOPF | CSPCY | CMOPF / CSPCY | |
| Capitalization | 828M | 9.91B | 8% |
| EBITDA | 42.1M | 7.63B | 1% |
| Gain YTD | -3.818 | 94.804 | -4% |
| P/E Ratio | 68.49 | 11.34 | 604% |
| Revenue | 104M | 31.1B | 0% |
| Total Cash | 222M | N/A | - |
| Total Debt | 176M | N/A | - |
CMOPF | CSPCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 48 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 73 | |
SMR RATING 1..100 | 55 | 93 | |
PRICE GROWTH RATING 1..100 | 56 | 35 | |
P/E GROWTH RATING 1..100 | 97 | 11 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CMOPF's Valuation (13) in the null industry is in the same range as CSPCY (29). This means that CMOPF’s stock grew similarly to CSPCY’s over the last 12 months.
CSPCY's Profit vs Risk Rating (73) in the null industry is in the same range as CMOPF (100). This means that CSPCY’s stock grew similarly to CMOPF’s over the last 12 months.
CMOPF's SMR Rating (55) in the null industry is somewhat better than the same rating for CSPCY (93). This means that CMOPF’s stock grew somewhat faster than CSPCY’s over the last 12 months.
CSPCY's Price Growth Rating (35) in the null industry is in the same range as CMOPF (56). This means that CSPCY’s stock grew similarly to CMOPF’s over the last 12 months.
CSPCY's P/E Growth Rating (11) in the null industry is significantly better than the same rating for CMOPF (97). This means that CSPCY’s stock grew significantly faster than CMOPF’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
Advertisement
CMOPF and
Correlation & Price change
A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.
| Ticker / NAME | Correlation To CMOPF | 1D Price Change % | ||
|---|---|---|---|---|
| CMOPF | 100% | N/A | ||
| GSK - CMOPF | 22% Poorly correlated | -3.84% | ||
| NVS - CMOPF | 21% Poorly correlated | -1.09% | ||
| CHGCY - CMOPF | 7% Poorly correlated | -1.45% | ||
| DSNKY - CMOPF | 5% Poorly correlated | -2.36% | ||
| CSPCY - CMOPF | 4% Poorly correlated | -0.77% | ||
More | ||||
CSPCY and
Correlation & Price change
A.I.dvisor tells us that CSPCY and CHJTF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSPCY and CHJTF's prices will move in lockstep.
| Ticker / NAME | Correlation To CSPCY | 1D Price Change % | ||
|---|---|---|---|---|
| CSPCY | 100% | -0.77% | ||
| CHJTF - CSPCY | 23% Poorly correlated | N/A | ||
| DSNKY - CSPCY | 16% Poorly correlated | -2.36% | ||
| BAYZF - CSPCY | 12% Poorly correlated | -1.83% | ||
| DSKYF - CSPCY | 5% Poorly correlated | -9.70% | ||
| CMOPF - CSPCY | 4% Poorly correlated | N/A | ||
More | ||||